![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Bioscience Laboratories, Meiji Seika Kaisha, Ltd., Sakado-city, Saitama 350-0289, Japan;
*
Department of Nutritional Science, Tokyo University of Agriculture, Setagaya-ku, Tokyo 156-8502, Japan;
Division of Clinical Chemistry, PB 60 FIN-00014, University of Helsinki, Helsinki, Finland;
**
Department of Pharmacology, School of Dentistry, Showa University, Shinagawa-ku, Tokyo 142-8555, Japan; and
Division of Food Science, National Institute of Health and Nutrition, Sinjyuku-ku, Tokyo 162-8636, Japan
1To whom correspondence should be addressed. E-mail: aohta{at}attglobal.net.
Fructooligosaccharides (FOS) stimulate the growth of bifidobacteria, which cleave isoflavone conjugates to yield the corresponding aglycones and metabolites. In a previous study, FOS modified the absorption and enterohepatic recirculation of isoflavones in rats. In the present study, we determined the effect of the combination of dietary FOS and isoflavone conjugates on bone mass in ovariectomized (OVX) and surgical control mice. After undergoing OVX or sham operation, female ddY mice (8 wk old, n = 64) were randomly assigned to four groups: a purified control diet (AIN-93G) group, a FOS diet (AIN-93G + 5% FOS) group, an isoflavone diet (AIN-93G + 0.2% isoflavone conjugates) group, or a FOS and isoflavone diet (AIN-93G + 5% FOS + 0.2% isoflavone conjugates) group. After 6 wk, the mice were killed and the blood and femora were sampled immediately. In OVX mice, both isoflavone conjugates and FOS prevented femoral bone loss. An additive effect of dietary isoflavone conjugates and FOS was observed by dual-energy X-ray absorptiometry in the distal part of the femur and in trabecular bone, by peripheral quantitative computed tomography. Moreover, FOS increased cecal ß-glucosidase activity and equol production from daidzein in both OVX and surgical control mice fed isoflavone conjugates. These results suggest that FOS increase the bioavailability of isoflavones, leading to cooperative effects in the prevention of osteopenia in OVX mice.
KEY WORDS: • bone mineral density • fructooligosaccharides • genistein • daidzein • equol • mice
This article has been cited by other articles:
|
|
 |
|
  L. L. Legette, B. R. Martin, M. Shahnazari, W.-H. Lee, W. G. Helferich, J. Qian, D. J. Waters, A. Arabshahi, S. Barnes, J. Welch, et al. Supplemental Dietary Racemic Equol Has Modest Benefits to Bone but Has Mild Uterotropic Activity in Ovariectomized Rats J. Nutr., October 1, 2009; 139(10): 1908 - 1913. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Watanabe, M. Nishimukai, H. Taguchi, T. Senoura, S. Hamada, H. Matsui, T. Yamamoto, J. Wasaki, H. Hara, and S. Ito Prebiotic Properties of Epilactose J Dairy Sci, December 1, 2008; 91(12): 4518 - 4526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Johnson, E. A. Lucas, S. Hooshmand, S. Campbell, M. P. Akhter, and B. H. Arjmandi Addition of Fructooligosaccharides and Dried Plum to Soy-based Diets Reverses Bone Loss in the Ovariectomized Rat Evid. Based Complement. Altern. Med., July 30, 2008; (2008) nen050v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Scholz-Ahrens and J. Schrezenmeir Inulin and Oligofructose and Mineral Metabolism: The Evidence from Animal Trials J. Nutr., November 1, 2007; 137(11): 2513S - 2523S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Coxam Current Data with Inulin-Type Fructans and Calcium, Targeting Bone Health in Adults J. Nutr., November 1, 2007; 137(11): 2527S - 2533S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Scholz-Ahrens, P. Ade, B. Marten, P. Weber, W. Timm, Y. A{varsigma}il, C.-C. Gluer, and J. Schrezenmeir Prebiotics, Probiotics, and Synbiotics Affect Mineral Absorption, Bone Mineral Content, and Bone Structure J. Nutr., March 1, 2007; 137(3): 838S - 846S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Clavel, M. Fallani, P. Lepage, F. Levenez, J. Mathey, V. Rochet, M. Serezat, M. Sutren, G. Henderson, C. Bennetau-Pelissero, et al. Isoflavones and Functional Foods Alter the Dominant Intestinal Microbiota in Postmenopausal Women J. Nutr., December 1, 2005; 135(12): 2786 - 2792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Setchell, C. Clerici, E. D Lephart, S. J Cole, C. Heenan, D. Castellani, B. E Wolfe, L. Nechemias-Zimmer, N. M Brown, T. D Lund, et al. S-Equol, a potent ligand for estrogen receptor {beta}, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora Am. J. Clinical Nutrition, May 1, 2005; 81(5): 1072 - 1079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Atkinson, C. L. Frankenfeld, and J. W. Lampe Gut Bacterial Metabolism of the Soy Isoflavone Daidzein: Exploring the Relevance to Human Health Experimental Biology and Medicine, March 1, 2005; 230(3): 155 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fujioka, M. Uehara, J. Wu, H. Adlercreutz, K. Suzuki, K. Kanazawa, K. Takeda, K. Yamada, and Y. Ishimi Equol, a Metabolite of Daidzein, Inhibits Bone Loss in Ovariectomized Mice J. Nutr., October 1, 2004; 134(10): 2623 - 2627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Allred, K. F. Allred, Y. H. Ju, T. S. Goeppinger, D. R. Doerge, and W. G. Helferich Soy processing influences growth of estrogen-dependent breast cancer tumors Carcinogenesis, September 1, 2004; 25(9): 1649 - 1657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Manach, A. Scalbert, C. Morand, C. Remesy, and L. Jimenez Polyphenols: food sources and bioavailability Am. J. Clinical Nutrition, May 1, 2004; 79(5): 727 - 747. [Abstract] [Full Text] [PDF]
|
|
